CONTEXT: Patients with progressive metastatic pheochromocytomas (PHEOs) or sympathetic paragangliomas (SPGLs) face a dismal prognosis. Current systemic therapies are limited. OBJECTIVES: The primary end point was progression-free survival determined by RECIST 1.1 criteria or positron emission tomography with [(18)F]fluorodeoxyglucose/computed tomography ([(18)F]FDG-PET/CT), in the absence of measurable soft tissue targets. Secondary endpoints were tumor response according to RECIST criteria version 1.1 or FDG uptake, blood pressure control, and safety. DESIGN: We conducted a retrospective review of medical records of patients with metastatic PHEO/SPGL treated with sunitinib from December 2007 through December 2011. An intention-to-treat analysis was performed. PATIENTS AND SETTING: Seventeen patients with progressive metastatic PHEO/SPGLs treated at the Institut Gustave-Roussy and MD Anderson Cancer Center. INTERVENTIONS: Patients treated with sunitinib. RESULTS: According to RECIST 1.1, eight patients experienced clinical benefit; three experienced partial response, and five had stable disease, including four with predominant skeletal metastases that showed a 30% or greater reduction in glucose uptake on [(18)F]FDG-PET/CT. Of 14 patients who had hypertension, six became normotensive and two discontinued antihypertensives. One patient treated with sunitinib and rapamycin experienced a durable benefit beyond 36 months. The median overall survival from the time sunitinib was initiated was 26.7 months with a progression-free survival of 4.1 months (95% confidence interval = 1.4-11.0). Most patients who experienced a clinical benefit were carriers of SDHB mutations. CONCLUSION: Sunitinib is associated with tumor size reduction, decreased [(18)F]FDG-PET/CT uptake, disease stabilization, and hypertension improvement in some patients with progressive metastatic PHEO/PGL. Prospective multi-institutional clinical trials are needed to determine the true benefits of sunitinib.
CONTEXT: Patients with progressive metastatic pheochromocytomas (PHEOs) or sympathetic paragangliomas (SPGLs) face a dismal prognosis. Current systemic therapies are limited. OBJECTIVES: The primary end point was progression-free survival determined by RECIST 1.1 criteria or positron emission tomography with [(18)F]fluorodeoxyglucose/computed tomography ([(18)F]FDG-PET/CT), in the absence of measurable soft tissue targets. Secondary endpoints were tumor response according to RECIST criteria version 1.1 or FDG uptake, blood pressure control, and safety. DESIGN: We conducted a retrospective review of medical records of patients with metastatic PHEO/SPGL treated with sunitinib from December 2007 through December 2011. An intention-to-treat analysis was performed. PATIENTS AND SETTING: Seventeen patients with progressive metastatic PHEO/SPGLs treated at the Institut Gustave-Roussy and MD Anderson Cancer Center. INTERVENTIONS:Patients treated with sunitinib. RESULTS: According to RECIST 1.1, eight patients experienced clinical benefit; three experienced partial response, and five had stable disease, including four with predominant skeletal metastases that showed a 30% or greater reduction in glucose uptake on [(18)F]FDG-PET/CT. Of 14 patients who had hypertension, six became normotensive and two discontinued antihypertensives. One patient treated with sunitinib and rapamycin experienced a durable benefit beyond 36 months. The median overall survival from the time sunitinib was initiated was 26.7 months with a progression-free survival of 4.1 months (95% confidence interval = 1.4-11.0). Most patients who experienced a clinical benefit were carriers of SDHB mutations. CONCLUSION:Sunitinib is associated with tumor size reduction, decreased [(18)F]FDG-PET/CT uptake, disease stabilization, and hypertension improvement in some patients with progressive metastatic PHEO/PGL. Prospective multi-institutional clinical trials are needed to determine the true benefits of sunitinib.
Authors: P-F Plouin; P Fitzgerald; T Rich; M Ayala-Ramirez; N D Perrier; E Baudin; C Jimenez Journal: Horm Metab Res Date: 2012-02-07 Impact factor: 2.936
Authors: Sungwoo Lee; Eijiro Nakamura; Haifeng Yang; Wenyi Wei; Michelle S Linggi; Mini P Sajan; Robert V Farese; Robert S Freeman; Bruce D Carter; William G Kaelin; Susanne Schlisio Journal: Cancer Cell Date: 2005-08 Impact factor: 31.743
Authors: Patrick J Pollard; Mona El-Bahrawy; Richard Poulsom; George Elia; Pip Killick; Gavin Kelly; Toby Hunt; Rosemary Jeffery; Pooja Seedhar; Julian Barwell; Farida Latif; Michael J Gleeson; Shirley V Hodgson; Gordon W Stamp; Ian P M Tomlinson; Eamonn R Maher Journal: J Clin Endocrinol Metab Date: 2006-09-05 Impact factor: 5.958
Authors: Ana M Molina; Darren R Feldman; Martin H Voss; Michelle S Ginsberg; Michael S Baum; Dion R Brocks; Patricia M Fischer; Michael J Trinos; Sujata Patil; Robert J Motzer Journal: Cancer Date: 2011-09-06 Impact factor: 6.860
Authors: Libo Zhang; Kristen M Smith; Amy L Chong; Diana Stempak; Herman Yeger; Paula Marrano; Paul S Thorner; Meredith S Irwin; David R Kaplan; Sylvain Baruchel Journal: Neoplasia Date: 2009-05 Impact factor: 5.715
Authors: Anthony M Joshua; Shereen Ezzat; Sylvia L Asa; Andrew Evans; Reuben Broom; Marc Freeman; Jennifer J Knox Journal: J Clin Endocrinol Metab Date: 2008-11-11 Impact factor: 5.958
Authors: Patricia L M Dahia; Ken N Ross; Matthew E Wright; César Y Hayashida; Sandro Santagata; Marta Barontini; Andrew L Kung; Gabriela Sanso; James F Powers; Arthur S Tischler; Richard Hodin; Shannon Heitritter; Francis Moore; Robert Dluhy; Julie Ann Sosa; I Tolgay Ocal; Diana E Benn; Deborah J Marsh; Bruce G Robinson; Katherine Schneider; Judy Garber; Seth M Arum; Márta Korbonits; Ashley Grossman; Pascal Pigny; Sérgio P A Toledo; Vania Nosé; Cheng Li; Charles D Stiles Journal: PLoS Genet Date: 2005-07-25 Impact factor: 5.917
Authors: Alexandra L Tabakin; Michael A Weintraub; Kushan D Radadia; Cristo G Salazar; Evita Sadimin; Eric A Singer Journal: Clin Oncol (Belmont) Date: 2019-03-08